conscience-angel-devil
28 February 2014EuropeBernd Allekotte

The Bolar exemption: the question of third parties

By order dated December 5, 2013, the Court of Appeals in Düsseldorf (docket no. I-2 U 68/12) referred various questions to the Court of Justice of the European Union (CJEU). The court asks for guidance on whether (and under what conditions) the supply of patented compounds by a third party to a (domestic) generic company, which intends to use the compounds for obtaining a marketing authorisation for a generic drug, is covered by the Bolar exemption.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
30 April 2026   Data from Questel indicates a radical restructuring of IP professionals’ duties, as adoption and demand rates continue to rise.
Europe
30 April 2026   The company’s rivals convinced an EPO appeals board to revoke a patent that had been used in litigation against them over Comirnaty.
Europe
24 April 2026   An opinion has put pressure on the CJEU to clarify a long-running grey area that could change the game for how drug makers secure supplementary protection certificates across Europe.